Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Markets / Mark To Market/  Dr Reddy’s Laboratories serves a bitter medicine in March quarter
BackBack

Dr Reddy’s Laboratories serves a bitter medicine in March quarter

Exclude ₹180.7 cr firm got by selling the US rights for 3 derma brands, and the revenue growth drops to an unexciting 8.5%
  • US revenue grew a mere 1% sequentially, despite some big product launches
  •  (Photo: Mint)Premium
    (Photo: Mint)

    Top pharmaceutical firms have bad news for investors who are looking for a recovery in business. After Lupin Ltd, Dr Reddy’s Laboratories Ltd has reported subdued performance for the March quarter.

    Reported revenues of Dr Reddy’s increased 14% from a year ago. But exclude the 180.7 crore the company received for the sale of its US rights for three dermatology brands, and revenue growth drops to an unexciting 8.5%. On a sequential basis, revenues are flat.

    Even otherwise, the sectoral performance is telling. US revenue grew a mere 1% sequentially, despite some big product launches. The disappointment does not end there. Revenue in India dropped 4% sequentially. On a year-on-year basis, India revenue is up just 6%, trailing industry growth and Street estimates by a sizeable margin. Together, both these geographies generate more than half of Dr Reddy’s revenue, and have dragged down overall growth numbers.

    View Full Image
    (Graphic: Naveen Kumar Saini/Mint)

    The lacklustre performance in the US implies limited boost from the new drugs, which the Street was banking upon. This also made the company susceptible to pricing and cost pressures. Gross margin narrowed 100 basis points from a year ago to 52.4%. In Q1 FY19, margins were as high as 55.7%. If one were to exclude the proceeds from the sale of dermatology brands, the drop in margin will be significantly higher.

    Not surprisingly, the performance disappointed the Street, which sent the stock down 2.5% on Friday. To recap, investors drove Dr Reddy’s shares up 38% in the past year, as the company moved to reduce costs, realign business priorities and brought it back to the growth path. But the progress in the March quarter suggests the recovery is a bit patchy.

    The management expects gross margins to improve in FY20, helped by cost-rationalization measures and higher growth in key markets. It is confident of sustaining growth momentum in India and other emerging markets. India revenue grew 12% in FY19, despite the setback in the March quarter. Revenue from emerging markets, which includes Russia, jumped 28%. The company is benefiting from expansion into new geographies and from the expansion of its product portfolio in these countries.

    While Dr Reddy’s post-results commentary sounds encouraging, what’s crucial for investors is an improvement in the US market. Its big-ticket products, such as Suboxone, are facing increasing competition in the US. This can limit the incremental revenue addition in FY20, warn analysts.

    Likewise, two crucial products, Nuvaring and Copaxone, which the company is working on, offers significant growth opportunities in FY20. But much depends on the eventual volumes of these products. Indian drug firms’ progress on new product sales has been patchy of late. This, coupled with the subdued performance in March, may cause some caution among Dr Reddy’s investors.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 19 May 2019, 10:40 PM IST
    Next Story footLogo
    Recommended For You
    GENIE RECOMMENDS

    Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

    Let’s get started
    Switch to the Mint app for fast and personalized news - Get App